Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.2527 | 0.5 | 0.5 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.2527 | 0.5 | 0.5 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.2527 | 0.5 | 0.5 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.2527 | 0.5 | 0.5 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.2527 | 0.5 | 0.5 |
Leishmania major | 0.2527 | 0.5 | 0.5 | |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.2527 | 0.5 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.2527 | 0.5 | 0.5 |
Toxoplasma gondii | fructose-bisphospatase II | 0.2527 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488991] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.